Faculty and fellows of the Division of Pediatric Hematology-Oncology are engaged in a wide range of clinical, translational and basic investigation related to pediatric cancer, disorders of the blood including clotting or bleeding problems, and the quality of life of children and their families undergoing severe medical conditions.
Areas of Special Interest
|Michael Armstrong, MD, PhD||Understanding the physiology of neuroblastoma and specific chemotherapy effects in order to develop more targeted therapies as well as participating in clinical studies aimed at applying recent scientific discoveries in order to improve the outcomes of children with neuroblastoma.|
|Raymond Barfield, MD||Study of the intersection of medicine, theology, philosophy, and literature in an attempt to improve the quality of life of children and their families experiencing severe medical illness.|
Developing improved genetic mouse models of Diffuse Intrinsic Pontine Glioma (DIPG) and applying them as preclinical tools to help prioritize the translation of novel agents into clinical trials for DIPG. Also, investigating mechanisms of resistance of novel targeted agents.
|Susan Kreissman, MD||
Improving the treatment of neuroblastoma through the study of new treatment plans, coordinating multidisciplinary care for retinoblastoma patients, leading national inquiry in COG neuroblastoma treatment studies.
|Catherine Praxede Lavau, PhD||Understanding the mechanisms underlying the pathogenesis of MLL-rearranged leukemias and related HOX overexpressing leukemias; leukemias caused by the CALM-AF10 fusion protein; mechanisms by which CRM1 contributes to the transcriptional activation of HOXA genes in leukemogenesis.|
|Corinne Linardic, MD, PhD||The study of childhood rhabdomyosarcoma, using primary cell-based and xenograft models to understand the implicated signaling pathways and to identify potential therapeutic targets.|
|Philip Rosoff, MD||Clinical ethics and medical decision making, as well as improving the psychosocial/physiologic functioning of long-term survivors of cancer. Moral implications of behavioral genetics and genetic determinism.|
|Jennifer Rothman, MD||
Benign hematology, including congenital hemolytic anemia, sickle cell disease, immune thrombocytopenia, aplastic anemia and bone marrow failure syndromes.
|Kristin Schroeder, MD||
Improving outcomes for pediatric cancer patients in low resource countries, including creating diagnostic algorithms to predict patients with lymphoma in areas where biopsy may not be readily available, as well as evaluating the factors contributing to high treatment abandonment rates among pediatric cancer patients.
|Nirmish Shah, MD||
Novel therapeutic options for patients with sickle cell disease; transition from pediatric to adult care for sickle cell disease; and use of mobile technology to advance patient care for sickle cell disease; use of wearables to provide objective data to combine with subjective symptoms in patients with sickle cell disease, cancer and bone marrow transplant who have pain.
|John J. Strouse, MD, PhD||My research focuses on the epidemiology, risk factors, and prevention of the pulmonary and central nervous system complications of sickle cell disease and includes retrospective and prospective cohort studies and clinical trials.|
|Jessica Sun, MD||
Developing umbilical cord blood-derived therapies for the treatment of childhood genetic and acquired neurologic disorders.
|David Van Mater, MD||
Factors that impact sarcoma formation; clinical studies that impact oncologic sequelae of neurofibromatosis.
For further information about clinical trials currently being conducted in the Division of Hematology-Oncology, please visit dukechildrens.org.